Skip to main content
. 2022 Feb 28;41(2):127–134. doi: 10.1007/s12664-021-01209-0

Table 3.

Blood parameters in patients with hepatocellular carcinoma 

Parameter
Hb (g/dL) 11.3 (2.1)
TLC (cells per mm3) 7300 (2900–26400)
PLT (cells per mm3)     1.645 (0.2500–17.1)
TB (mg/dL)     1.500 (0.17–24.10)
Alb (g/dL)     3.280 (1.7–4.9)
AST (U/L)   77.00 (4–810)
ALT (U/L)   39 (6–731)
ALP (U/L) 157.0 (40–1187)
AST (> 2 times UNL) (%)   45.1%
ALT (> 2 times UNL) (%)   12.7%
ALP (> 2 times UNL) (%)   49.3%
INR >1.5 (%)   14.5%
AFP (ng/mL) 353.3 (0.8–395444)
AFP < 20 ng/mL (%)   27.4%
20–400 ng/mL (%)   23.7%
400–1000 ng/mL (%)     8.3%
>1000 ng/mL (%)   40.6%

Hb hemoglobin expressed in g/dL mean (SD), TLC total leukocyte count, PLT platelet count, TB total bilirubin, Alb albumin, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, INR international normalized ratio, AFP alpha- fetoproteinin, UNL upper normal limit, TLC PLT, TB, Alb, AST, ALT, ALP and AFP expressed as median (interquartile range), % of patients with AFP levels <20, 20–400, 400–1000, and >1000 ng/mL